［1］徐德忠.分子流行病学［M］.北京：人民军医出版社，1998.

［2］FDA-NIH Biomarker Working Group, Biological markers in environmental health research. Committee on Biological Markers of the National Research Council［J］. Environ Health Perspect，1987，74：3-9.

［3］ALBERTINI RJ, The use and interpretation of biomarkers of environmental genotoxicity in humans［J］. Biotherapy，1998，11（2-3）：155-167.

［4］Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints：preferred definitions and conceptual framework［J］. ClinPharmacolTher，2001，69（3）：89-95.

［5］FDA-NIH Biomarker Working Group, BEST（Biomarkers, Endpoints, and other tools）Resource. 2018.

［6］CAGNEYDN, SUL J, HUANG RY, et al. The FDA NIH biomarkers, endpoints, and other Tools（BEST）resource in neuro-oncology［J］. NeuroOncol，2018，20（9）：1162-1172.

［7］WILD CP. Complementing the genome with an “exposome”：the outstanding challenge of environmental exposure measurement in molecular epidemiology［J］. Cancer Epidemiol Biomarkers Prev，2005，14（8）：1847-1850.

［8］WILD CP. The exposome：from concept to utility［J］. IntJ Epidemiol，2012，41（1）：24-32.

［9］STOLER MH, WRIGHT TC, SHARMA A, et al. High-risk human papillomavirus testing in women with ASC-US cytology：results from the ATHENA HPV Study［J］. Am J Clin Pathol，2011，135（3）：468-475.

［10］SMITHLE, DENISSENKO MF, BennettWP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons［J］. JNatl Cancer Inst，2000，92（10）：803-811.

［11］PETRICOIN EF, ARDEKANI AM, HITT BA, et al, Use of proteomic patterns in serum to identify ovarian cancer［J］. The Lancet，2002，359（9306）：572-577.

［12］RANADE AR, CHERBA D, SRIDHAR S, et al. MicroRNA 92a-2 a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer［J］.JThoracOncol，2010，5（8）：1273-1278.

［13］TAN X, QIN W, ZHANG L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis［J］. CliniCancer Res，2011，17（21）：6802-6811.

［14］VRIJHEID M, SLAMA R, ROBINSON O, et al. The Human Early-Life Exposome（HELIX）：Project Rationale and Design［J］. Environmental health perspectives，2014，122（6）：535-544.

［15］KAWAMO T, NITTA H, MURATA K, et al. Rationale and study design of the Japan environment and children study（JECS）［J］. BMC public health，2014，14：25-32.

［16］TAM KW, ZHANG W, SOH J, et al. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer［J］. J ThoracOncol，　2013，8（11）：1378-1388.

［17］JOHNSON CH, ATHERSUCH TJ, COLLMAN GW, et al, Yale school of public health symposium on lifetime exposures and human health：the exposome；summary and future reflections［J］. Hum Genomics，2017，11（1）：32-39.

［18］VRIJHEID M. The exposome：a new paradigm to study the impact of environment on health［J］. Thorax，2014，69（9）：876-878.

［19］MAPESA JO, MAXWELL AL, RYAN EP. An exposomeperspective on environmental enteric dysfunction［J］. Environ Health Perspect，2016，124（8）：1121-1126.

［20］IZHARUDDINL E, MARIMUTHU K, FONG PB, et al. Comparative risk factors for nosocomial New Delhi metallo-beta-lactamase（NDM-1）producing enterobacteriaceae and noncarbapenemase producing（NCP）enterobacteriaceae［J］. Antimicrob Resist Infect Control，2015，4（suppl）：134.

［21］WOLFF MS, TEITELBAUM SL, PINNEY SM, et al. Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls［J］. Environ Health Perspect, 2010, 118 (7): 1039-1046.

［22］CALIFF RM. Biomarker definitions and their applications［J］. Exp Biol Med，2018，243（3）：213-221.